Ascletis Pharma Inc. (ASCLF) Stock Price & Analysis
Ascletis Pharma Inc. (ASCLF) — price $0.625 (0.00%), as of the Nov 19, 2026 trading session; market cap $654M.
Educational signal · not a buy or sell recommendation · How to read this
Ascletis Pharma Inc. · ASCLF
Ascletis Pharma Inc. is a biotechnology company focused on the research, development, manufacture, and sale of pharmaceutical products in Mainland China and internationally.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.625 | |
| Change on the day | 0.00% | |
| 52-week range | $0.62 – $2.50 | |
| Market capitalisation | $654M | |
| Shares traded on the day | 5.0K |
Price & events
Other perspectives
Council score for Ascletis Pharma (ASCLF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Ascletis Pharma (ASCLF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ascletis Pharma Inc. (ASCLF) is the company analyzed here. It employs 202 people and is led by Jinzi J. Wu. In Q4 FY2025 it reported revenue of CN¥931,267 and net income of -CN¥267M. The market values it at $654M.
What do the latest results show for Ascletis Pharma (ASCLF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of CN¥931,267. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | CN¥931,267 | -CN¥267M | -CN¥0.27 (diluted) |
| Q2 FY2025 | CN¥1M | -CN¥88M | -CN¥0.09 (diluted) |
| Q4 FY2024 | CN¥1M | -CN¥171M | -CN¥0.17 (diluted) |
What are the financial strengths and risks for Ascletis Pharma (ASCLF)?
Short answer · as of
The distress and quality screens read Altman Z 13.36 · Piotroski F 1. Trailing ratios: ROE -28.2% · ROA -24.1% · current ratio 12.92 · earnings yield -14.2% · free-cash-flow yield -12.0%.
Data-derived red flags
- Negative return on equity (-28.2%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Ascletis Pharma (ASCLF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $724,237 · EPS -0.57 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $724,237
- EPS estimate
- $-0.57
Measured against a quoted price of $0.625 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ASCLF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ASCLF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Ascletis Pharma Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is ASCLF a good stock to buy?
Stock Expert AI does not rate ASCLF buy, sell or hold. Ascletis Pharma Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ASCLF stock price today?
The last price recorded for Ascletis Pharma Inc. (ASCLF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for ASCLF?
Evaluate ASCLF on fundamentals, analyst consensus, and risk factors. The company does not currently pay a dividend, consistent with many growth-focused biotechnology companies that reinvest earnings into R&D and pipeline expansion. Not financial advice.
How frequently does ASCLF data refresh on this page?
ASCLF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ASCLF's recent stock price performance?
Ascletis Pharma Inc. (ASCLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse and extensive drug pipeline addressing multiple significant unmet medical needs across viral diseases, metabolic disorders, and oncology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ASCLF overvalued or undervalued right now?
Ascletis Pharma Inc. (ASCLF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ASCLF before investing?
Before investing in Ascletis Pharma Inc. (ASCLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ASCLF to a portfolio?
Key strength of Ascletis Pharma Inc. (ASCLF): Diverse and extensive drug pipeline addressing multiple significant unmet medical needs across viral diseases, metabolic disorders, and oncology. Weigh rewards against risks and diversify. Not financial advice.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP) and 9 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com